药易购(300937) - 2025 Q4 - 年度业绩预告

Financial Projections - The company expects a net profit of between 2.8 million to 4.2 million CNY for the year 2025, representing a decline of 74.32% to 82.88% compared to the previous year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be between 1.6 million to 2.4 million CNY, reflecting a decrease of 80.60% to 87.07% year-on-year[5]. Profitability Challenges - The decline in profitability is attributed to changes in the overall market environment, industry policies, and shifts in retail structure and consumer behavior[4]. - Increased income tax expenses are due to the company's ineligibility for preferential tax rates under the Western Development policy, leading to higher tax liabilities[6]. - The company has terminated some loss-making projects, but residual costs from these projects continue to negatively impact current profits[6]. - The company has recognized impairment losses on goodwill based on the requirements of accounting standards for the fiscal year 2025[6]. Business Development - The company is in the early stages of developing new business areas, with ongoing R&D and market expansion costs that have not yet generated significant revenue[4]. Financial Reporting - The financial data presented is preliminary and has not been audited by the accounting firm, with detailed figures to be disclosed in the 2025 annual report[7].